Date: 2017-10-13
Type of information: Series D financing round
Company: InflaRX (Germany)
Investors: Bain Capital Life Sciences (USA) Cormorant Asset Management (USA) RA Capital Management (USA) undisclosed investment funds managed by a leading US investment management firm
Amount: $ 55 million
Funding type: series D financing round
Planned used:
- Proceeds from the capital increase will be used to advance clinical phase IIb development of InflaRx’s lead drug candidate IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in chronic inflammatory and auto-immune indications and to advance preclinical development of follow-up pipeline molecules.
- In July 2017, InflaRx successfully completed a clinical Phase IIa open label trial in patients suffering from Hidradenitis Suppurativa, a chronic debilitating auto-inflammatory skin disease, which demonstrated the disease modifying activity of lead drug candidate IFX-1. This data was presented at two European meetings in September, the 16th European Meeting on Complement in Human Disease, Copenhagen and the 26th Meeting of the European Academy of Dermatology and Venerology, Geneva.
Others:
- • On October 13 2017, InflaRx announced a $ 55M Series D financing and investment round. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC and complemented by certain investment funds managed by a leading US investment management firm.
- The transaction is comprised of a $ 30M capital increase and a $ 25M secondary share purchase.
Therapeutic area: Inflammatory diseases
Is general: Yes
